生物標記開發平臺分析 - 2026 年（第二季更新）

生物標記開發流程是指生物標記從發現、分析檢驗、臨床檢驗、法規核准到商業化等各階段的系統性過程，旨在支持精準醫療。現代生物標記開發整合了基因組學、蛋白質組學、轉錄組學、代謝體學組學、成像技術、計算生物學和人工智慧，建構了一個能夠產生具有臨床意義的生物學證據的綜合科學工作流程。隨著製藥公司不斷拓展標靶治療的範圍，對生物標記的需求日益成長，這些生物標記需要在臨床前研究、臨床開發、監管申報和上市後證據生成等各個階段檢驗。生物標記在多個治療領域中發揮越來越重要的作用，例如支持患者選擇、最佳化治療方案、疾病監測和伴隨診斷的開發。製藥公司正在加強與生命科學技術公司、診斷實驗室和學術研究機構的合作，這些機構擁有先進的實驗室能力、生物資訊學專業知識和轉化研究基礎設施。生物標記開發流程的策略重要性不僅體現在藥物創新上，也體現在伴隨診斷、疾病預後預測、病患監測和個人化醫療等領域。因此，擴展生物標記管線是支撐精準醫療和分子醫學長期發展的重要基礎。

市場促進因素

擴大精準醫療和伴隨診斷的發展。

• 精準醫療越來越依賴生物標記來識別最有可能從標靶治療中獲益的患者群體，這使得生物標記的開發成為藥物創新不可或缺的要素。從藥物發現到臨床檢驗和法規核准，對協調一致的藥物開發流程的需求日益成長，這正推動著整合式生物標記研發管線的發展。傳統的生物標記研究常常導致研發中斷和治療藥物商業化的延誤。製藥公司正在強化其生物標記開發項目，將其整合為統一的精準醫療平台，整合實驗科學、計算生物學、轉化醫學和伴隨診斷策略。這種轉變正在推動生物標記開發平臺的持續擴展。

多體學技術整合的進展

• 現代生物標記研發流程擴大整合基因組學、蛋白質組學、轉錄組學、代謝體學和表觀遺傳學數據，以提升分子層面的表徵能力和治療決策的準確性。單一平台生物標記策略往往難以捕捉疾病複雜的生物機制，因此，整合多體學分析的需求日益成長。製藥公司正增加對先進定序技術、質譜分析、計算生物學和人工智慧的投資，以增強生物標記的發現並改善下游檢驗流程。技術提供者也在加速研發流程的推進，同時拓展其分析能力，以支援日益複雜的精準醫療應用。這些科學進步正在推動整個生物標記研發生態系統的持續發展。

製藥業加大對生物標記驅動藥物研發的投資

• 生物標記正日益影響藥物研發的整個流程，從標靶識別和受試者招募到臨床終點選擇、劑量最佳化和治療監測。由於檢驗的生物標記能夠提高研發效率並降低臨床不確定性，製藥公司不斷加強其生物標記計畫。因此，治療創新越來越依賴結構化的生物標記研發管線，而非孤立的實驗室發現。製藥公司正在將生物標記開發融入更廣泛的藥物研發策略，以加強科學發現、臨床研究和監管合規規劃之間的協調。這種整合方法正在推動對生物標記研發管線的長期需求。

監管機構對生物標記合格評估的認知不斷提高

• 監管機構日益認知到，檢驗的生物標記是支持藥物研發和精準醫療的關鍵科學工具。隨著整個藥物研發過程中監管決策對分析可靠且具有臨床意義的生物學證據的需求不斷成長，生物標記的適用範圍也在不斷擴大。製藥公司正在加強其生物標記合格檢驗，以產生可重複的科學證據，從而支持向國際監管機構提交的申請。技術提供者也持續投資於實驗室標準化、計算分析和轉化研究，以提高生物標記的品質並加快合格。這些進展正在推動整個生物標記開發平臺的持續投資。

市場限制因素

• 分析和臨床檢驗的高科學複雜性持續延長生物標記開發所需時間並增加研究成本。生物標記合格和檢驗缺乏足夠的全球標準化，導致藥物開發項目監管方面存在不確定性。管理大規模基因組和多組體學資料集仍然需要大規模的運算基礎設施、專業知識和資料管治能力。

目錄

第1章：引言

• 調查方法
• 調查範圍
  • 分析：按公司
  • 分析：依技術/診斷方法
  • 分析：按臨床研究狀態
  • 分析：透過應用
  • 分析：按地區
• 數據來源和檢驗
• 定義和假設

第2章：診斷過程概述

• 目前診斷概述
• 臨床應用與尚未解決的診斷難題
• 技術進步
• 臨床有效性要求

第3章執行摘要

• 管道概覽
• 主要診斷技術/平台
• 主要公司和研究贊助商
• 臨床檢驗活動
• 地理調查概述
• 管道構建中的關鍵趨勢和發現

第4章：生物標記開發平臺的動態變化

• 促進因素
• 抑制因子
• 潛在機會

第5章 管道分析/預測

• 管道分析：按公司分類
  • Guardant Health
  • Natera
  • GRAIL
  • Exact Sciences
  • Roche Diagnostics
  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Foundation Medicine
  • Freenome
• 管道分析：按技術/診斷方法
  • 基因生物標記
  • 蛋白質體學生物標記
  • 轉錄組生物標記
  • 表觀遺傳生物標記
  • 循環/液態生物檢體生物標記物
  • 多組體學物標誌物
• 管道分析：依適應症/應用範圍分類
  • 診斷/檢測
  • 預後
  • 預測/治療方案
  • 治療反應監測
  • 復發/疾病監測
• 管道分析：依樣品/檢體類型
  • 組織
  • 血液/血漿
  • 其他生物檢體
• 研發管線分析：依臨床試驗狀態分類
  • 我們尚未開始招募參與者。
  • 招募測試對象
  • 目前已暫停招募參與者。
  • 完成
  • 取消/撤回/暫停
• 臨床有效性檢驗和患者分析
  • 按入組人數進行的研究
  • 前瞻性研究與回顧性研究
  • 主要臨床終點
  • 患者/樣本隊列分析
• 管道分析：按地區分類
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 贊助和合作關係分析
  • 主要商業贊助商
  • 主要學術和研究贊助商
  • 診斷公司和製藥公司之間的合作關係
  • 贊助商和合作研究者分析
• 近期和未來管道趨勢
  • 最近啟動的檢驗測試
  • 目前正在接受申請的新研究項目
  • 最近完成的檢驗測試
  • 調查即將完成。
  • 近期發表的研究成果

第6章：公司簡介

• Guardant Health
• Natera
• GRAIL
• Exact Sciences
• Roche Diagnostics
• Illumina
• Thermo Fisher Scientific
• QIAGEN
• Foundation Medicine
• Freenome

第7章 圖表清單

第8章：圖表清單

The biomarker development pipeline represents the structured progression of biological markers through discovery, analytical validation, clinical validation, regulatory qualification, and commercial implementation supporting precision healthcare. Modern biomarker development integrates genomics, proteomics, transcriptomics, metabolomics, imaging technologies, computational biology, and artificial intelligence into comprehensive scientific workflows capable of generating clinically meaningful biological evidence. Demand is increasing because pharmaceutical companies continue expanding targeted therapeutics that require validated biomarkers throughout preclinical research, clinical development, regulatory submissions, and post-market evidence generation. Biomarkers increasingly support patient selection, treatment optimization, disease monitoring, and companion diagnostic development across multiple therapeutic areas. Pharmaceutical developers are strengthening collaborations with life science technology companies, diagnostic organizations, and academic research institutions that possess advanced laboratory capabilities, bioinformatics expertise, and translational research infrastructure. The strategic importance of biomarker pipelines extends beyond pharmaceutical innovation into companion diagnostics, disease prognosis, patient monitoring, and personalized healthcare. Biomarker pipeline expansion therefore represents a critical foundation supporting the long-term evolution of precision medicine and molecular healthcare.

Market Drivers

Expanding Precision Medicine and Companion Diagnostic Development

• Precision medicine increasingly depends on biomarkers that identify patient populations most likely to benefit from targeted therapies, making biomarker development an essential component of pharmaceutical innovation. Demand is shifting toward integrated biomarker pipelines because therapeutic development increasingly requires coordinated progression from discovery through clinical validation and regulatory qualification. Conventional biomarker research frequently creates development gaps that delay therapeutic commercialization. Pharmaceutical companies are strengthening integrated biomarker development programs that combine laboratory science, computational biology, translational medicine, and companion diagnostic strategies into unified precision medicine platforms. This transformation supports sustained expansion of biomarker development pipelines.

Increasing Integration of Multi-Omics Technologies

• Modern biomarker pipelines increasingly combine genomic, proteomic, transcriptomic, metabolomic, and epigenetic data to improve molecular characterization and therapeutic decision-making. Demand is increasing because single-platform biomarker strategies frequently fail to capture complex disease biology, creating greater reliance on integrated multi-omics analysis. Pharmaceutical developers increasingly invest in advanced sequencing technologies, mass spectrometry, computational biology, and artificial intelligence that strengthen biomarker discovery while improving downstream validation. Technology providers continue expanding analytical capabilities that accelerate pipeline progression while supporting increasingly sophisticated precision medicine applications. These scientific advances reinforce sustained demand across the biomarker development ecosystem.

Rising Pharmaceutical Investment in Biomarker-Guided Drug Development

• Biomarkers increasingly influence target identification, patient recruitment, clinical endpoint selection, dose optimization, and treatment monitoring throughout pharmaceutical development. Drug developers continue strengthening biomarker programs because validated biomarkers improve development efficiency while reducing clinical uncertainty. Therapeutic innovation therefore increasingly depends on structured biomarker pipelines rather than isolated laboratory discoveries. Pharmaceutical organizations are integrating biomarker development into broader drug development strategies that improve coordination between scientific discovery, clinical research, and regulatory planning. This integrated approach strengthens long-term demand for biomarker pipeline development.

Growing Regulatory Recognition of Biomarker Qualification

• Regulatory agencies increasingly recognize validated biomarkers as important scientific tools supporting pharmaceutical development and precision medicine. Biomarker qualification continues expanding because regulatory decision-making increasingly requires analytically reliable and clinically meaningful biological evidence throughout therapeutic development. Pharmaceutical organizations are strengthening biomarker validation strategies capable of generating reproducible scientific evidence supporting international regulatory submissions. Technology providers continue investing in laboratory standardization, computational analytics, and translational research that improve biomarker quality while accelerating qualification. These developments reinforce continued investment throughout biomarker development pipelines.

Market Restraints

• High scientific complexity associated with analytical and clinical validation continues extending biomarker development timelines while increasing research costs. Limited global standardization for biomarker qualification and validation continues creating regulatory uncertainty across therapeutic development programs. Management of large-scale genomic and multi-omics datasets continues requiring substantial computational infrastructure, specialized expertise, and data governance capabilities.

Technology and Segment Insights

By Development Stage

• Discovery, Analytical Validation, Clinical Validation, Regulatory Qualification, and Commercial Deployment collectively define the biomarker development pipeline. Discovery establishes candidate biomarkers through multi-omics research, while analytical and clinical validation confirm scientific reproducibility and clinical utility before regulatory qualification. Demand is increasing for integrated development strategies because pharmaceutical companies seek efficient progression across every development stage rather than fragmented research activities. Regulatory qualification and commercial deployment continue becoming increasingly important as companion diagnostics and precision therapeutics expand across multiple therapeutic areas. Industry participants continue strengthening multidisciplinary development capabilities that improve scientific quality while accelerating biomarker commercialization.

By Biomarker Type

• Genomic Biomarkers, Proteomic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers, Imaging Biomarkers, and Digital Biomarkers represent the principal categories. Genomic and proteomic biomarkers continue dominating development activity because targeted therapeutics increasingly require molecular characterization supporting patient selection and treatment optimization. Transcriptomic, metabolomic, and epigenetic biomarkers are becoming increasingly important as multi-omics technologies improve biological understanding and disease characterization. Imaging and digital biomarkers continue expanding because non-invasive monitoring and digital health technologies increasingly support precision medicine applications.

By Therapeutic Area

• Oncology continues representing the largest area of biomarker development because targeted therapies increasingly require companion biomarkers supporting personalized treatment strategies. Neurology, cardiovascular diseases, and autoimmune disorders are generating increasing biomarker demand as disease complexity drives adoption of precision medicine approaches. Rare disease research continues expanding because genomic biomarkers improve diagnosis and accelerate therapeutic development for genetically defined patient populations. These complementary therapeutic trends continue supporting sustained growth throughout the global biomarker development pipeline.

Competitive and Strategic Outlook

• The competitive landscape features major life science technology companies. Thermo Fisher Scientific Inc. distinguishes itself through its comprehensive portfolio of genomics, proteomics, analytical instrumentation, and bioinformatics technologies supporting biomarker development from discovery through clinical validation. Roche Diagnostics differentiates itself through its leadership in molecular diagnostics, companion diagnostics, genomics, and integrated pharmaceutical-diagnostic development. Revvity, Inc. distinguishes itself through its advanced genomics, proteomics, imaging technologies, and precision medicine solutions. QIAGEN N.V. differentiates itself through its expertise in molecular diagnostics, sample preparation, genomics, companion diagnostics, and bioinformatics. Illumina, Inc. distinguishes itself through its leadership in next-generation sequencing (NGS), genomic analysis, and bioinformatics technologies. Bio-Rad Laboratories, Inc. distinguishes itself through its expertise in life science research, digital PCR, and immunoassays.
• Strategic developments include increasing integration of artificial intelligence and machine learning, expansion of multi-omics platforms, and growth of translational research collaborations. Companies are forming partnerships with pharmaceutical developers, academic institutions, and biotechnology firms to accelerate biomarker validation and commercialization. Technology expansions focus on next-generation sequencing, high-resolution mass spectrometry, spatial biology, digital pathology, and cloud-enabled bioinformatics. Companies that successfully integrate analytical technologies, computational biology, translational medicine, and regulatory science within scalable platforms are expected to lead the market.

Conclusion

• The biomarker development pipeline is poised for significant growth, driven by the expansion of precision medicine, multi-omics integration, and pharmaceutical investment in biomarker-guided drug development. The evolution from isolated research initiatives toward integrated precision medicine ecosystems is reshaping the landscape. Companies that successfully deliver validated, scalable, and clinically meaningful biomarker solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding translational research infrastructure will further accelerate development throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Research Methodology
• 1.2. Research Scope
  • 1.2.1. Analysis by Company
  • 1.2.2. Analysis by Technology / Diagnostic Approach
  • 1.2.3. Analysis by Clinical Study Status
  • 1.2.4. Analysis by Application
  • 1.2.5. Analysis by Geography
• 1.3. Data Sources and Validation
• 1.4. Definitions and Assumptions

2. DIAGNOSTIC LANDSCAPE OVERVIEW

• 2.1. Introduction
• 2.2. Current Diagnostic Landscape
• 2.3. Clinical Use and Unmet Diagnostic Needs
• 2.4. Technology Evolution
• 2.5. Clinical Validation Requirements

3. EXECUTIVE SUMMARY

• 3.1. Pipeline Overview
• 3.2. Leading Diagnostic Technologies / Platforms
• 3.3. Leading Companies and Study Sponsors
• 3.4. Clinical Validation Activity
• 3.5. Geographic Study Landscape
• 3.6. Key Pipeline Trends and Findings

4. BIOMARKER DEVELOPMENT PIPELINE DYNAMICS

• 4.1. Drivers
• 4.2. Restraints
• 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

• 5.1. PIPELINE ANALYSIS BY COMPANY
  • 5.1.1. Guardant Health
  • 5.1.2. Natera
  • 5.1.3. GRAIL
  • 5.1.4. Exact Sciences
  • 5.1.5. Roche Diagnostics
  • 5.1.6. Illumina
  • 5.1.7. Thermo Fisher Scientific
  • 5.1.8. QIAGEN
  • 5.1.9. Foundation Medicine
  • 5.1.10. Freenome
• 5.2. PIPELINE ANALYSIS BY TECHNOLOGY / DIAGNOSTIC APPROACH
  • 5.2.1. Genomic Biomarkers
  • 5.2.2. Proteomic Biomarkers
  • 5.2.3. Transcriptomic Biomarkers
  • 5.2.4. Epigenetic Biomarkers
  • 5.2.5. Circulating / Liquid Biopsy Biomarkers
  • 5.2.6. Multi-Omics Biomarkers
• 5.3. PIPELINE ANALYSIS BY APPLICATION / INDICATION
  • 5.3.1. Diagnosis / Detection
  • 5.3.2. Prognosis
  • 5.3.3. Predictive / Treatment Selection
  • 5.3.4. Treatment Response Monitoring
  • 5.3.5. Recurrence / Disease Monitoring
• 5.4. PIPELINE ANALYSIS BY SAMPLE / SPECIMEN TYPE
  • 5.4.1. Tissue
  • 5.4.2. Blood / Plasma
  • 5.4.3. Other Biological Samples
• 5.5. PIPELINE ANALYSIS BY CLINICAL STUDY STATUS
  • 5.5.1. Not Yet Recruiting
  • 5.5.2. Recruiting
  • 5.5.3. Active, Not Recruiting
  • 5.5.4. Completed
  • 5.5.5. Terminated / Withdrawn / Suspended
• 5.6. CLINICAL VALIDATION AND PATIENT ANALYSIS
  • 5.6.1. Studies by Enrollment
  • 5.6.2. Prospective versus Retrospective Studies
  • 5.6.3. Major Clinical Endpoints
  • 5.6.4. Patient / Sample Cohort Analysis
• 5.7. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia-Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa
• 5.8. SPONSOR AND COLLABORATION ANALYSIS
  • 5.8.1. Leading Commercial Sponsors
  • 5.8.2. Leading Academic and Research Sponsors
  • 5.8.3. Diagnostic-Pharma Collaborations
  • 5.8.4. Sponsor-Collaborator Analysis
• 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
  • 5.9.1. Recently Initiated Validation Studies
  • 5.9.2. Newly Recruiting Studies
  • 5.9.3. Recently Completed Validation Studies
  • 5.9.4. Studies Approaching Primary Completion
  • 5.9.5. Studies with Recently Posted Results

6. COMPANY PROFILES

• 6.1. Guardant Health
• 6.2. Natera
• 6.3. GRAIL
• 6.4. Exact Sciences
• 6.5. Roche Diagnostics
• 6.6. Illumina
• 6.7. Thermo Fisher Scientific
• 6.8. QIAGEN
• 6.9. Foundation Medicine
• 6.10. Freenome

7. LIST OF TABLES

8. LIST OF FIGURES